Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Aravive Inc (ARAV)

Aravive Inc (ARAV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,950
  • Shares Outstanding, K 73,563
  • Annual Sales, $ 9,140 K
  • Annual Income, $ -76,320 K
  • 60-Month Beta 2.19
  • Price/Sales 0.50
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade ARAV with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.90
  • Most Recent Earnings $-0.10 on 11/09/23
  • Latest Earnings Date 05/08/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0400 +0.25%
on 01/23/24
0.1292 -68.96%
on 01/02/24
-0.0882 (-68.75%)
since 12/26/23
3-Month
0.0400 +0.25%
on 01/23/24
0.1820 -77.97%
on 11/30/23
-0.0969 (-70.73%)
since 10/26/23
52-Week
0.0400 +0.25%
on 01/23/24
2.4600 -98.37%
on 03/21/23
-1.6699 (-97.65%)
since 01/26/23

Most Recent Stories

More News
Aravive (ARAV) Reports Q1 Loss, Tops Revenue Estimates

Aravive (ARAV) delivered earnings and revenue surprises of 33.33% and 98.80%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

ARAV : 0.0401 (-13.39%)
CELL : 0.9981 (+0.31%)
Syros Pharmaceuticals, Inc. (SYRS) Reports Q1 Loss, Tops Revenue Estimates

Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of 24.11% and 0.14%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...

SYRS : 4.55 (-3.60%)
ARAV : 0.0401 (-13.39%)
What Makes Aravive (ARAV) a New Buy Stock

Aravive (ARAV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

ARAV : 0.0401 (-13.39%)
Aravive (ARAV) Reports Q4 Loss, Tops Revenue Estimates

Aravive (ARAV) delivered earnings and revenue surprises of -39.39% and 298.38%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

ARAV : 0.0401 (-13.39%)
LQDA : 13.78 (-0.22%)
Selecta Biosciences, Inc. (SELB) Reports Q4 Loss, Tops Revenue Estimates

Selecta Biosciences, Inc. (SELB) delivered earnings and revenue surprises of 25% and 32.02%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?...

SELB : 0.8812 (-8.00%)
ARAV : 0.0401 (-13.39%)
Beat the Market the Zacks Way: Boeing, General Electric, AmerisourceBergen, Kimberly-Clark in Focus

Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.

BA : 171.31 (+0.63%)
ITW : 250.08 (+0.50%)
GE : 150.96 (-1.29%)
DGX : 127.78 (+1.49%)
ABC : 179.98 (-0.23%)
KMB : 125.60 (-0.01%)
CNHI : 12.34 (-0.48%)
RNST : 29.38 (+2.12%)
NOBL : 96.96 (+0.62%)
PARR : 31.66 (+1.90%)
ARAV : 0.0401 (-13.39%)
Wave of FDA Fast Track Designations Sparks Renewed Interest in Biotech Sector That's Heating Up

/PRNewswire/ -- USA News Group - A series of new Fast Track designations have been handed out by the United States Food and Drug Administration (FDA) this...

ONC.TO : 1.42 (-0.70%)
ONCY : 1.0300 (unch)
RHHBY : 30.3450 (+0.98%)
ARAV : 0.0401 (-13.39%)
CRBU : 3.91 (-0.13%)
KTRA : 0.1204 (+12.95%)
Wave of FDA Fast Track Designations Sparks Renewed Interest in Biotech Sector That’s Heating Up

FN Media Group Presents USA News Group News Commentary   Vancouver, BC –December 1, 2022 – USA News Group  –  A series of new Fast Track designations have been handed out by the United States...

ONCY : 1.0300 (unch)
ONC.TO : 1.42 (-0.70%)
RHHBY : 30.3450 (+0.98%)
ARAV : 0.0401 (-13.39%)
CRBU : 3.91 (-0.13%)
KTRA : 0.1204 (+12.95%)
Latest Set of FDA Fast Track Designations Causing Optimism in Biotech Sector

USA News Group – A series of new Fast Track designations have been handed out by the United States Food and Drug Administration (FDA) this week, causing a flurry of activity in the markets for the worthy...

ONCY : 1.0300 (unch)
ONC.TO : 1.42 (-0.70%)
RHHBY : 30.3450 (+0.98%)
ARAV : 0.0401 (-13.39%)
CRBU : 3.91 (-0.13%)
KTRA : 0.1204 (+12.95%)
Aravive (ARAV) Reports Q3 Loss, Tops Revenue Estimates

Aravive (ARAV) delivered earnings and revenue surprises of 20.31% and 298.39%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

ARAV : 0.0401 (-13.39%)
MIRO : 3.39 (+0.59%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Aravive Inc. is a biotechnology company. It develops therapeutic proteins for the treatment of metabolic diseases and endocrine disorders. Aravive Inc. is based in TX, United States.

See More

Key Turning Points

3rd Resistance Point 0.0499
2nd Resistance Point 0.0480
1st Resistance Point 0.0440
Last Price 0.0401
1st Support Level 0.0381
2nd Support Level 0.0362
3rd Support Level 0.0322

See More

52-Week High 2.4600
Fibonacci 61.8% 1.5356
Fibonacci 50% 1.2500
Fibonacci 38.2% 0.9644
Last Price 0.0401
52-Week Low 0.0400

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar